FindTrial
Sign In

The effect of the treatment of idiopathic membranous nephropathy was observed in the treatment of idiopathic membranous nephropathy, and the effect of the treatment on Th17 / Treg

The effect of the treatment of idiopathic membranous nephropathy was observed in the treatment of idiopathic membranous nephropathy, and the effect of the treatment on Th17 / Treg

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17011400
Enrollment
Unknown
Registered
2017-05-14
Start date
2017-07-01
Completion date
Unknown
Last updated
2017-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Membranous nephropathy

Interventions

The control group:Glucocorticoid + tacosa treatment
The treatment group:Glucocorticoid + tacmox + Chinese medicine

Sponsors

Shijiazhuang Kidney Disease Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-70 years male and female; 2. A 24-hour urine protein is greater than or equal to 3.5 grams; 3. Blood creatinine is less than 442umol/L; 4. The renal biopsy pathology of sanjia hospital proved to be membranous nephropathy; 5. The combination of the hormone combined immunosuppressant therapy for 3 months was invalid.

Exclusion criteria

Exclusion criteria: 1. Patients with secondary membranous nephropathy; 2. Patients with acute and chronic infectious diseases; 3. A malignant tumor; 4. Severe diabetes, hypertension, and liver dysfunction; 5. pregnancy. People with mental illness.

Design outcomes

Primary

MeasureTime frame
24 hours of urine protein quantification;—

Countries

China

Contacts

Public ContactLiu Yongzhi

Shijiazhuang Kidney Disease Hospital

liuyongzhidaifu@163.com+86 18932939105

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026